Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

Anna Bergamaschi, Geir Olav Hjortland, Tiziana Triulzi, Therese Sørlie, Hilde Johnsen, Anne Hansen Ree, Hege Giercksky Russnes, Sigurd Tronnes, Gunhild M. Mælandsmo, Oystein Fodstad, Anne Lise Borresen-Dale, Olav Engebraaten

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The number of relevant and well-characterized cell lines and xenograft models for studying human breast cancer are few, and may represent a limitation for this field of research. With the aim of developing new breast cancer model systems for in vivo studies of hormone dependent and independent tumor growth, progression and invasion, and for in vivo experimental therapy studies, we collected primary mammary tumor specimens from patients, and implanted them in immunodeficient mice. Primary tumor tissue from 29 patients with breast cancer was implanted subcutaneously with matrigel in SCID mice, in the presence of continuous release of estradiol. The tumors were transferred into new animals when reaching a diameter of 15 mm and engrafted tumors were harvested for morphological and molecular characterization from passage six. Further, gene expression profiling was performed using Agilent Human Whole Genome Oligo Microarrays, as well as DNA copy number analysis using Agilent Human Genome CGH 244K Microarrays. Of the 30 primary tumors implanted into mice (including two implants from the same patient), two gave rise to viable tumors beyond passage ten. One showed high expression levels of estrogen receptor-α protein (ER) while the other was negative. Histopathological evaluation of xenograft tumors was carried out at passage 10-12; both xenografts maintained the morphological characteristics of the original tumors (classified as invasive grade III ductal carcinomas). The genomic profile of the ER-positive xenograft tumor resembled the profile of the primary tumor, while the profile obtained from the ER-negative parental tumor was different from the xenograft. However, the ER-negative parental tumor and xenograft clustered on the same branch using unsupervised hierarchical clustering analysis on RNA microarray expression data of "intrinsic genes". A significant variation was observed in the expression of extracellular matrix (ECM)-related genes, which were found downregulated in the engrafted tumors compared to the primary tumor. By IHC and qRT-PCR we found that the downregulation of stroma-related genes was compensated by the overexpression of such molecules by the mouse host tissue. The two established breast cancer xenograft models showed different histopathological characteristics and profound diversity in gene expression patterns that in part can be associated to their ER status and here described as basal-like and luminal-like phenotype, respectively. These two new breast cancer xenografts represent useful preclinical tools for developing and testing of new therapies and improving our knowledge on breast cancer biology.

Original languageEnglish
Pages (from-to)469-482
Number of pages14
JournalMolecular Oncology
Volume3
Issue number5-6
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Heterografts
Breast Neoplasms
Neoplasms
Human Genome
Down-Regulation
Genes
Ductal Carcinoma
Investigational Therapies
SCID Mice
Gene Expression Profiling
Extracellular Matrix
Cluster Analysis
Estradiol
estrophilin
Hormones
RNA

Keywords

  • Basal
  • Breast cancer
  • Genome array
  • Luminal
  • Model system
  • RNA microarray

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Bergamaschi, A., Hjortland, G. O., Triulzi, T., Sørlie, T., Johnsen, H., Ree, A. H., ... Engebraaten, O. (2009). Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular Oncology, 3(5-6), 469-482. https://doi.org/10.1016/j.molonc.2009.07.003

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. / Bergamaschi, Anna; Hjortland, Geir Olav; Triulzi, Tiziana; Sørlie, Therese; Johnsen, Hilde; Ree, Anne Hansen; Russnes, Hege Giercksky; Tronnes, Sigurd; Mælandsmo, Gunhild M.; Fodstad, Oystein; Borresen-Dale, Anne Lise; Engebraaten, Olav.

In: Molecular Oncology, Vol. 3, No. 5-6, 12.2009, p. 469-482.

Research output: Contribution to journalArticle

Bergamaschi, A, Hjortland, GO, Triulzi, T, Sørlie, T, Johnsen, H, Ree, AH, Russnes, HG, Tronnes, S, Mælandsmo, GM, Fodstad, O, Borresen-Dale, AL & Engebraaten, O 2009, 'Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models', Molecular Oncology, vol. 3, no. 5-6, pp. 469-482. https://doi.org/10.1016/j.molonc.2009.07.003
Bergamaschi, Anna ; Hjortland, Geir Olav ; Triulzi, Tiziana ; Sørlie, Therese ; Johnsen, Hilde ; Ree, Anne Hansen ; Russnes, Hege Giercksky ; Tronnes, Sigurd ; Mælandsmo, Gunhild M. ; Fodstad, Oystein ; Borresen-Dale, Anne Lise ; Engebraaten, Olav. / Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. In: Molecular Oncology. 2009 ; Vol. 3, No. 5-6. pp. 469-482.
@article{e35dcc041d2e4dcebedd76c32f82a0c2,
title = "Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models",
abstract = "The number of relevant and well-characterized cell lines and xenograft models for studying human breast cancer are few, and may represent a limitation for this field of research. With the aim of developing new breast cancer model systems for in vivo studies of hormone dependent and independent tumor growth, progression and invasion, and for in vivo experimental therapy studies, we collected primary mammary tumor specimens from patients, and implanted them in immunodeficient mice. Primary tumor tissue from 29 patients with breast cancer was implanted subcutaneously with matrigel in SCID mice, in the presence of continuous release of estradiol. The tumors were transferred into new animals when reaching a diameter of 15 mm and engrafted tumors were harvested for morphological and molecular characterization from passage six. Further, gene expression profiling was performed using Agilent Human Whole Genome Oligo Microarrays, as well as DNA copy number analysis using Agilent Human Genome CGH 244K Microarrays. Of the 30 primary tumors implanted into mice (including two implants from the same patient), two gave rise to viable tumors beyond passage ten. One showed high expression levels of estrogen receptor-α protein (ER) while the other was negative. Histopathological evaluation of xenograft tumors was carried out at passage 10-12; both xenografts maintained the morphological characteristics of the original tumors (classified as invasive grade III ductal carcinomas). The genomic profile of the ER-positive xenograft tumor resembled the profile of the primary tumor, while the profile obtained from the ER-negative parental tumor was different from the xenograft. However, the ER-negative parental tumor and xenograft clustered on the same branch using unsupervised hierarchical clustering analysis on RNA microarray expression data of {"}intrinsic genes{"}. A significant variation was observed in the expression of extracellular matrix (ECM)-related genes, which were found downregulated in the engrafted tumors compared to the primary tumor. By IHC and qRT-PCR we found that the downregulation of stroma-related genes was compensated by the overexpression of such molecules by the mouse host tissue. The two established breast cancer xenograft models showed different histopathological characteristics and profound diversity in gene expression patterns that in part can be associated to their ER status and here described as basal-like and luminal-like phenotype, respectively. These two new breast cancer xenografts represent useful preclinical tools for developing and testing of new therapies and improving our knowledge on breast cancer biology.",
keywords = "Basal, Breast cancer, Genome array, Luminal, Model system, RNA microarray",
author = "Anna Bergamaschi and Hjortland, {Geir Olav} and Tiziana Triulzi and Therese S{\o}rlie and Hilde Johnsen and Ree, {Anne Hansen} and Russnes, {Hege Giercksky} and Sigurd Tronnes and M{\ae}landsmo, {Gunhild M.} and Oystein Fodstad and Borresen-Dale, {Anne Lise} and Olav Engebraaten",
year = "2009",
month = "12",
doi = "10.1016/j.molonc.2009.07.003",
language = "English",
volume = "3",
pages = "469--482",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "5-6",

}

TY - JOUR

T1 - Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

AU - Bergamaschi, Anna

AU - Hjortland, Geir Olav

AU - Triulzi, Tiziana

AU - Sørlie, Therese

AU - Johnsen, Hilde

AU - Ree, Anne Hansen

AU - Russnes, Hege Giercksky

AU - Tronnes, Sigurd

AU - Mælandsmo, Gunhild M.

AU - Fodstad, Oystein

AU - Borresen-Dale, Anne Lise

AU - Engebraaten, Olav

PY - 2009/12

Y1 - 2009/12

N2 - The number of relevant and well-characterized cell lines and xenograft models for studying human breast cancer are few, and may represent a limitation for this field of research. With the aim of developing new breast cancer model systems for in vivo studies of hormone dependent and independent tumor growth, progression and invasion, and for in vivo experimental therapy studies, we collected primary mammary tumor specimens from patients, and implanted them in immunodeficient mice. Primary tumor tissue from 29 patients with breast cancer was implanted subcutaneously with matrigel in SCID mice, in the presence of continuous release of estradiol. The tumors were transferred into new animals when reaching a diameter of 15 mm and engrafted tumors were harvested for morphological and molecular characterization from passage six. Further, gene expression profiling was performed using Agilent Human Whole Genome Oligo Microarrays, as well as DNA copy number analysis using Agilent Human Genome CGH 244K Microarrays. Of the 30 primary tumors implanted into mice (including two implants from the same patient), two gave rise to viable tumors beyond passage ten. One showed high expression levels of estrogen receptor-α protein (ER) while the other was negative. Histopathological evaluation of xenograft tumors was carried out at passage 10-12; both xenografts maintained the morphological characteristics of the original tumors (classified as invasive grade III ductal carcinomas). The genomic profile of the ER-positive xenograft tumor resembled the profile of the primary tumor, while the profile obtained from the ER-negative parental tumor was different from the xenograft. However, the ER-negative parental tumor and xenograft clustered on the same branch using unsupervised hierarchical clustering analysis on RNA microarray expression data of "intrinsic genes". A significant variation was observed in the expression of extracellular matrix (ECM)-related genes, which were found downregulated in the engrafted tumors compared to the primary tumor. By IHC and qRT-PCR we found that the downregulation of stroma-related genes was compensated by the overexpression of such molecules by the mouse host tissue. The two established breast cancer xenograft models showed different histopathological characteristics and profound diversity in gene expression patterns that in part can be associated to their ER status and here described as basal-like and luminal-like phenotype, respectively. These two new breast cancer xenografts represent useful preclinical tools for developing and testing of new therapies and improving our knowledge on breast cancer biology.

AB - The number of relevant and well-characterized cell lines and xenograft models for studying human breast cancer are few, and may represent a limitation for this field of research. With the aim of developing new breast cancer model systems for in vivo studies of hormone dependent and independent tumor growth, progression and invasion, and for in vivo experimental therapy studies, we collected primary mammary tumor specimens from patients, and implanted them in immunodeficient mice. Primary tumor tissue from 29 patients with breast cancer was implanted subcutaneously with matrigel in SCID mice, in the presence of continuous release of estradiol. The tumors were transferred into new animals when reaching a diameter of 15 mm and engrafted tumors were harvested for morphological and molecular characterization from passage six. Further, gene expression profiling was performed using Agilent Human Whole Genome Oligo Microarrays, as well as DNA copy number analysis using Agilent Human Genome CGH 244K Microarrays. Of the 30 primary tumors implanted into mice (including two implants from the same patient), two gave rise to viable tumors beyond passage ten. One showed high expression levels of estrogen receptor-α protein (ER) while the other was negative. Histopathological evaluation of xenograft tumors was carried out at passage 10-12; both xenografts maintained the morphological characteristics of the original tumors (classified as invasive grade III ductal carcinomas). The genomic profile of the ER-positive xenograft tumor resembled the profile of the primary tumor, while the profile obtained from the ER-negative parental tumor was different from the xenograft. However, the ER-negative parental tumor and xenograft clustered on the same branch using unsupervised hierarchical clustering analysis on RNA microarray expression data of "intrinsic genes". A significant variation was observed in the expression of extracellular matrix (ECM)-related genes, which were found downregulated in the engrafted tumors compared to the primary tumor. By IHC and qRT-PCR we found that the downregulation of stroma-related genes was compensated by the overexpression of such molecules by the mouse host tissue. The two established breast cancer xenograft models showed different histopathological characteristics and profound diversity in gene expression patterns that in part can be associated to their ER status and here described as basal-like and luminal-like phenotype, respectively. These two new breast cancer xenografts represent useful preclinical tools for developing and testing of new therapies and improving our knowledge on breast cancer biology.

KW - Basal

KW - Breast cancer

KW - Genome array

KW - Luminal

KW - Model system

KW - RNA microarray

UR - http://www.scopus.com/inward/record.url?scp=70350571374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350571374&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2009.07.003

DO - 10.1016/j.molonc.2009.07.003

M3 - Article

VL - 3

SP - 469

EP - 482

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 5-6

ER -